Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex

Kaori Kitaoka,Yuichiro Yano,Hajime Nagasu,Hiroshi Kanegae,Noriharu Chishima,Hiroki Akiyama,Kouichi Tamura,Naoki Kashihara

DOI: https://doi.org/10.1136/bmjdrc-2024-004115

2024-05-31

BMJ Open Diabetes Research & Care

Abstract:Introduction We compared the kidney outcomes between patients with diabetic kidney disease (DKD) aged ≥75 years initiating sodium-glucose cotransporter 2 (SGLT2) inhibitors versus other glucose-lowering drugs, additionally presenting with or without proteinuria. Research design and methods Using the Japan Chronic Kidney Disease Database, we developed propensity scores, implementing a 1:1 matching protocol. The primary outcome included the decline rate in estimated glomerular filtration rate (eGFR), and secondary outcomes incorporated a composite of a 40% reduction in eGFR or progression to end-stage kidney disease. Results At baseline, the mean age at initiation of SGLT2 inhibitors (n=348) or other glucose-lowering medications (n=348) was 77.7 years. The mean eGFR was 59.3 mL/min/1.73m 2 and proteinuria was 230 (33.0%) patients. Throughout the follow-up period, the mean annual rate of eGFR change was –0.80 mL/min/1.73 m 2 /year (95% CI –1.05 to –0.54) among SGLT2 inhibitors group and –1.78 mL/min/1.73 m 2 /year (95% CI –2.08 to –1.49) in other glucose-lowering drugs group (difference in the rate of eGFR decline between the groups was 0.99 mL/min/1.73 m 2 /year (95% CI 0.5 to 1.38)), favoring SGLT2 inhibitors (p<0.001). Composite renal outcomes were observed 38 in the SGLT2 inhibitors group and 57 in the other glucose-lowering medications group (HR 0.64, 95% CI 0.42 to 0.97). There was no evidence of an interaction between SGLT2 inhibitors initiation and proteinuria. Conclusions The benefits of SGLT2 inhibitors on renal outcomes are also applicable to older patients with DKD aged≥75 years.

endocrinology & metabolism

What problem does this paper attempt to address?

The paper aims to explore the differences in renal outcomes between SGLT2 inhibitors and other hypoglycemic agents in patients aged 75 and above with diabetic kidney disease (DKD). Specifically, the study evaluates the effect of SGLT2 inhibitors by comparing the rate of decline in estimated glomerular filtration rate (eGFR) and the incidence of composite renal events between two groups of patients during treatment.

The study found that in DKD patients aged 75 and above, the use of SGLT2 inhibitors significantly slowed the rate of eGFR decline and reduced the risk of composite renal events compared to other hypoglycemic agents. Additionally, the research indicated that these benefits were more pronounced in patients with proteinuria, baseline eGFR <60 mL/min/1.73 m², or those using angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). This finding is of great significance for clinical practice, suggesting that SGLT2 inhibitors are equally effective in providing renal protection for elderly DKD patients.